Yat Sun Or, Ph.D., is a distinguished scientist who currently serves as the Chief Scientific Officer at Enanta Pharmaceuticals Inc. Dr. Or has been with Enanta since 2014, bringing a wealth of experience in drug discovery and development to the company. Prior to joining Enanta, he held significant roles at Achillion Pharmaceuticals, where he was instrumental in advancing multiple drug candidates through clinical trials. His expertise spans various therapeutic areas, including infectious diseases, oncology, and rare diseases, making him a valuable asset to Enanta's research and development efforts. Dr. Or's academic credentials are equally impressive. He earned his Ph.D. in Organic Chemistry from Columbia University and completed his postdoctoral training at Harvard University. Throughout his career, Dr. Or has authored numerous scientific publications and holds several patents, reflecting his contributions to the field of medicinal chemistry. His work has been pivotal in the development of novel antiviral therapies, particularly in the fight against hepatitis C and other infectious diseases. As Chief Scientific Officer at Enanta, Dr. Or plays a critical role in steering the company's scientific strategy and overseeing its drug discovery programs. Under his leadership, Enanta has made significant strides in developing innovative treatments for viral infections and other serious diseases. His vision and dedication to advancing healthcare through cutting-edge research continue to drive Enanta's mission to deliver life-changing therapies to patients worldwide.